HIV-1 integrase and RNase H activities as therapeutic targets

Expert Opinion on Therapeutic Targets

Volumn 6, Issue 4, 2002, Pages 433-446

  Andreola M L ^a   De Soultrait, V R ^a   Fournier, M ^a   Parissi, V ^a   Desjobert, C ^a   Litvak, S ^a  

^a UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

HIV 1; Inhibitors; Integrase; RNase H; Therapeutic targets

Indexed keywords

4 [1 (4 FLUOROBENZYL) 2 PYRROLYL] 2,4 DIOXOBUTYRIC ACID; ANTHRAQUINONE DERIVATIVE; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; CAFFEIC ACID PHENETHYL ESTER; CARBOXYLIC ACID; CATECHOL DERIVATIVE; CHLOROQUINE; CICHORIC ACID; CURCUMIN; DIDANOSINE; DNA TOPOISOMERASE INHIBITOR; ENZYME INHIBITOR; FLAVONE DERIVATIVE; HEXAPEPTIDE; INTEGRASE; L 708906; LEXITROPSIN; LIGNAN DERIVATIVE; NEVIRAPINE; OXOACID; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIBONUCLEASE H; RNA DIRECTED DNA POLYMERASE; T 30695; TYRPHOSTIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRUS RNA; ZIDOVUDINE 5' PHOSPHATE; ZIDOVUDINE 5' TRIPHOSPHATE; ZINTEVIR;

ANTIVIRAL ACTIVITY; CONTROLLED STUDY; DNA INTEGRATION; DRUG SYNTHESIS; ENZYME ACTIVITY; GENETIC CODE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PROTEIN TARGETING; REVERSE TRANSCRIPTION; REVIEW; RNA VIRUS; VIRUS MORPHOLOGY; VIRUS REPLICATION;

ANTI-HIV AGENTS; CELL LINE; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; HIV INFECTIONS; HIV INTEGRASE; HIV INTEGRASE INHIBITORS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; RECOMBINANT FUSION PROTEINS; REVERSE TRANSCRIPTASE INHIBITORS; RIBONUCLEASE H, CALF THYMUS; SACCHAROMYCES CEREVISIAE; SELEX APTAMER TECHNIQUE; VIRUS INTEGRATION; VIRUS REPLICATION;

EID: 0036049662     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.6.4.433     Document Type: Review

References (103)

1. HIV-1 integrase: Structural organization, conformational changes, and catalysis
2. Nuclear import of human immunodeficiency virus type-1 preintegration complexes
3. HIV-1 nuclear import: In search of a leader
4. Viral entry into the nucleus
5. Human immunodeficiency virus type 1 preintegration complexes: Studies of organization and composition
6. HIV-1 cDNA integration: Requirement of HMG I(Y) protein for function of preintegration complexes in vitro
7. The barrier-to-autointegration protein is a host factor for HIV Type 1 integration
8. Historical introduction to the general properties of retroviruses
9. Crystal structure at 3.5 Å resolution of HIV-1 reverse transcriptase complexed with an inhibitor
10. Reconstitution in vitro of RNase H activity by using purified N-terminal and C-terminal domains of human immunodeficiency virus Type 1 reverse transcriptase
11. Crystal structure of the ribonuclease H domain of HIV-1 reverse transcriptase
12. Human immunodeficiency virus Type 1 reverse transcriptase: Spatial and temporal relationship between the polymerase and RNase H activities
13. Crystal structure of human immunodeficiency virus Type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 Å resolution shows bent DNA
14. Parameters that influence processive synthesis and site-specific termination by human immunodeficiency virus reverse transcriptase on RNA and DNA templates
15. Mechanism of DNA strand transfer reactions catalyzed by HIV-1 reverse transcriptase
16. Effects on DNA synthesis and translocation caused by mutations in the RNase H domain of Moloney murine leukemia virus reverse transcriptase
17. Structural implications of spectroscopic characterization of a putative zinc finger peptide from HIV-1 integrase
18. Domains of the integrase protein of human immunodeficiency virus Type 1 responsible for polynucleotidyl transfer and zinc binding
19. Zinc folds the N-terminal domain of HIV-1 integrase, promotes multimerization, and enhances catalytic activity
20. Crystal structure of the HIV-1 integrase catalytic core and C-terminal domains: A model for viral DNA binding
21. X-ray structure of simian immunodeficiency virus integrase containing the core and C-terminal domain (residues 50-293) - An initial glance of the viral DNA binding platform
22. Crystal structure of an active two-domain derivative of Rous sarcoma virus integrase
23. Recombining the structures of HIV integrase, RuvC and RNase H
24. Inhibitors of human immunodeficiency virus integrase
25. Triplex-mediated inhibition of HIV DNA integration in vitro
26. Alternate strand DNA triple helix-mediated inhibition of HIV-1 U5 long terminal repeat integration in vitro
27. Branched oligonucleotide-intercalator conjugate forming a parallel stranded structure inhibits HIV-1 integrase
28. Highly potent synthetic polyamides, bisdistamycins, and lexitropsins as inhibitors of human immunodeficiency virus Type 1 integrase
29. Synthesis and evaluation of oligo-1,3-thiazolecarboxamide derivatives as HIV-1 reverse transcriptase inhibitors
30. Inhibition of HIV-1 integrase-catalysed reaction by new DNA minor groove ligands: The oligo-1,3-thiazolecarboxamide derivatives
31. Inhibition of HIV-1 integration protein by aurintricarboxylic acid monomers, monomer analogs, and polymer fractions
32. Effects of tyrphostins, protein kinase inhibitors, on human immunodeficiency virus Type 1 integrase
33. HIV cDNA integration: Molecular biology and inhibitor development
34. (-)-Arctigenin as a lead structure for inhibitors of human immunodeficiency virus Type-1 integrase
35. Inhibition of human immunodeficiency virus integrase by biscatechols
36. Synthesis and HIV-1 integrase inhibitory activities of catechol and bis-catechol derivatives
37. Structure-activity relationships and binding mode of styrylquinolines as potent inhibitors of HIV-1 integrase and replication of HIV-1 in cell culture
38. Inhibition of HIV-1 integrase by flavones, caffeic acid phenethyl ester (CAPE) and related compounds
39. Inhibition of human immunodeficiency virus type-1 integrase by curcumin
40. Curcumin analogs with altered potencies against HIV-1 integrase as probes for biochemical mechanisms of drug action
41. Inhibitors of HIV-1 replication inhibit HIV integrase
42. Viral entry as the primary target for the anti-HIV activity of chicoric acid and its tetra-acetyl esters
43. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells
44. HIV-1 integrase inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integrase
45. Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene
46. 4-Aryl-2,4-dioxobutanoic acid inhibitors of HIV-1 integrase and viral replication in cells
47. Structural determinants for HIV-1 integrase inhibition by β-diketo acids
48. Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: A platform for antiviral drug design
49. Ordered water and ligand mobility in the HIV-1 integrase-5CITEP complex: A molecular dynamics study
50. Fully flexible low-mode docking: Application to induced fit in HIV integrase
51. Targeting cyclin-dependent kinases in Drosophila with peptide aptamers
52. Identification of a hexapeptide inhibitor of the human immunodeficiency virus integrase protein by using a combinatorial chemical library
53. A synthetic peptide from the human immunodeficiency virus type-1 integrase exhibits coiled-coil properties and interferes with the in vitro integration activity of the enzyme. Correlated biochemical and spectroscopic results
54. Peptide inhibitors of HIV-1 integrase dissociate the enzyme oligomers
55. Inhibition of human immunodeficiency virus Type 1 reverse transcriptase dimerization using synthetic peptides derived from the connection domain
56. The thumb domain of the P51-subunit is essential for activation of HIV reverse transcriptase
57. A novel short peptide is a specific inhibitor of the human immunodeficiency virus Type 1 integrase
58. Bacteriophage display and discovery of peptide leads for drug development
59. Phage-display technology-finding a needle in a vast molecular haystack
60. Applications of display technology in protein analysis
61. Identification of a nucleotide binding site in HIV-1 integrase
62. Discovery of a nuclease-resistant, non-natural dinucleotide that inhibits HIV-1 integrase
63. Developing G-quartet oligonucleotides as novel anti-HIV agents: Focus on anti-HIV drug design
64. Human immunodeficiency virus glycoprotein gp120 as the primary target for the antiviral action of AR177 (Zintevir)
65. Potassium-dependant folding: A key to intracellular delivery of G-quartet oligonucleotides as HIV inhibitors
66. Oligonucleotides as antiretroviral agents
67. Isolation of high-affinity RNA ligands to HIV-1 integrase from a random pool
68. Biochemical characterization of the HIV-1 integrase 3′-processing activity and its inhibition by phosphorothioate oligonucleotides
69. Inhibition of HIV-1 integrase by modified oligonucleotides derived from U5′ LTR
70. Inhibition of HIV-1 integration by mono- & bi-functionalized triple helix forming oligonucleotides
71. High affinity interaction of HIV-1 integrase with specific and non-specific single-stranded short oligonucleotides
72. Coupled integration of human immunodeficiency virus Type 1 cDNA ends by purified integrase in vitro: Stimulation by the viral nucleocapsid protein
73. Expression of functional HIV-1 integrase in the yeast Saccharomyces cerevisiae leads to the emergence of a lethal phenotype: Potential use for inhibitor screening
74. Inactivation of the RNase H domain of HIV-1 reverse transcriptase blocks viral infectivity
75. Inhibition of human immunodeficiency virus Type 1 RNase H by sulfated polyanions
76. The ribonuclease H activity of HIV-1 reverse transcriptase: Further biochemical characterization and search of inhibitors
77. Inhibition of the RNase H activity of HIV reverse transcriptase by azidothymidylate
78. A specific RNA structural motif mediates high affinity binding by the HIV-1 nucleocapsid protein (NCp7)
79. The interaction of illimaquinone, a selective inhibitor of the RNase H activity, with the reverse transcriptases of human immunodeficiency and murine leukemia retroviruses
80. Inhibition of human immunodeficiency virus Type 1 reverse transcriptase and ribonuclease H activities by constituents of Juglans mandshurica
81. Inhibition of the ribonuclease H and DNA polymerase activities of HIV-1 reverse transcriptase by N-(4-tert-butylbenzoyl)-2-hydroxy-1-naphthaldehyde hydrazone
82. Mutational analysis of Y501 of HIV-1 reverse transcriptase: Effects on ribonuclease H activity and inhibition of this activity by N-acyl hydrazones
83. Domain structure of the Moloney murine leukemia virus reverse transcriptase: Mutational analysis and separate expression of the DNA polymerase and RNase H activities
84. Nevirapine alters the cleavage specificity of ribonuclease H of human immunodeficiency virus 1 reverse transcriptase
85. The P236L delavirdine-resistant human immunodeficiency virus Type 1 mutant is replication defective and demonstrates alterations in both RNA 5′-end- and DNA 3′-end-directed RNase H activities
86. Mutants of human immunodeficiency virus Type 1 (HIV-1) reverse transcriptase resistant to nonnucleoside reverse transcriptase inhibitors demonstrate altered rates of RNase H cleavage that correlate with HIV-1 cell culture
87. Inhibitors of DNA strand transfer reactions catalyzed by HIV-1 reverse transcriptase
88. Inhibition of HIV-1 reverse transcriptase-catalyzed DNA strand transfer reactions by 4-chlorophenylhydrazone of mesoxalic acid
89. In vitro evolution of functional nucleic acids: High-affinity RNA ligands of HIV-1 proteins
90. Bent pseudoknots and novel RNA inhibitors of Type 1 human immunodeficiency virus (HIV-1) reverse transcriptase
91. High-affinity ssDNA inhibitors of the reverse transcriptase of Type 1 human immunodeficiency virus
92. In vitro selection of RNA molecules that bind specific ligands
93. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase
94. From oligonucleotide shapes to genomic SELEX: Novel biological regulatory loops
95. Aptamers as tools in molecular biology and immunology
96. Aptamers: An emerging class of molecules that rival antibodies in diagnostics
97. Aptamers: Selected oligonucleotides for therapy
98. Detection and plasma pharmacokinetics of an anti-vascular endothelial growth factor oligonucleotide-aptamer (NX1838) in rhesus monkeys
99. Escort aptamers: A delivery service for diagnosis and therapy
100. RNA pseudoknots that inhibit human immunodeficiency virus Type 1 reverse transcriptase
101. Selection of high-affinity RNA ligands to reverse transcriptase: Inhibition of cDNA synthesis and RNase H activity
102. DNA aptamers selected against the HIV-1 RNase H display in vitro antiviral activity
103. S-adenosylmethionine reverses ilimaquinone's vesiculation of the Golgi apparatus. A fluorescence study on the cellular interactions of ilimaquinone